M. Shapiro
YOU?
Author Swipe
View article: W+D Charm Jet Fragmentation
W+D Charm Jet Fragmentation Open
Using ATLAS Run 2 data, proton-proton collisions at 13 TeV center of mass energy are analyzed to measure the properties of Charmed particle fragmentation. The process $pp\\rightarrow &W;\\pmc$, where the c-quark fragments to a $D^+$ hadron…
View article: Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies Open
Viral diseases represent a major public health concern and an ever-present risk for developing into a future pandemic. Antiviral antibody therapeutics, either alone or in combination with other therapies, have emerged as valuable preventat…
View article: Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
View article: Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive ac…
View article: Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 5 describes the 5 randomized trials of GO plus chemotherapy reviewed as part of the safety assessment of GO in combination with chemotherapy.
View article: Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
View article: Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 3 describes the adverse events with corresponding risk differences between treatment arms during consolidation 2 of pivotal trial ALFA-0701.
View article: Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
View article: Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 5 describes the 5 randomized trials of GO plus chemotherapy reviewed as part of the safety assessment of GO in combination with chemotherapy.
View article: Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 2 describes the adverse events with corresponding risk differences between treatment arms during consolidation 1 of pivotal trial ALFA-0701.
View article: Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 3 describes the adverse events with corresponding risk differences between treatment arms during consolidation 2 of pivotal trial ALFA-0701.
View article: Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive ac…
View article: Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
View article: Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia Open
Supplemental Table 2 describes the adverse events with corresponding risk differences between treatment arms during consolidation 1 of pivotal trial ALFA-0701.
View article: Track reconstruction for the CDF silicon tracking system
Track reconstruction for the CDF silicon tracking system Open
The Collider Detector at Fermilab (CDF) Collaboration will install a new silicon micro-strip tracking system for Run 2 at Fermilab starting in 1999. The new detector will require powerful new pattern recognition algorithms to exploit its f…
View article: Measurement of the nuclear modification factor for muons from charm and bottom hadrons in Pb+Pb collisions at 5.02 TeV with the ATLAS detector
Measurement of the nuclear modification factor for muons from charm and bottom hadrons in Pb+Pb collisions at 5.02 TeV with the ATLAS detector Open
View article: Search for new phenomena in three- or four-lepton events in $pp$ collisions at $\sqrt s$ =13 TeV with the ATLAS detector
Search for new phenomena in three- or four-lepton events in $pp$ collisions at $\sqrt s$ =13 TeV with the ATLAS detector Open
A search with minimal model dependence for physics beyond the Standard Model in events featuring three or four charged leptons (3ℓ and 4ℓ, ℓ=e,μ) is presented. The analysis aims to be sensitive to a wide range of potential new-physics theo…
View article: Measurement of the $t\bar{t}t\bar{t}$ production cross section in $pp$ collisions at $\sqrt{s}$=13 TeV with the ATLAS detector
Measurement of the $t\bar{t}t\bar{t}$ production cross section in $pp$ collisions at $\sqrt{s}$=13 TeV with the ATLAS detector Open
A measurement of four-top-quark production using proton-proton collision data at a centre-of-mass energy of 13 TeV collected by the ATLAS detector at the Large Hadron Collider corresponding to an integrated luminosity of 139 fb$^{-1}$ is p…
View article: Search for heavy particles in the $b$-tagged dijet mass distribution with additional $b$-tagged jets in proton-proton collisions at $\sqrt{s} = 13$ TeV with the ATLAS experiment
Search for heavy particles in the $b$-tagged dijet mass distribution with additional $b$-tagged jets in proton-proton collisions at $\sqrt{s} = 13$ TeV with the ATLAS experiment Open
A search optimized for new heavy particles decaying to two $b$-quarks and produced in association with additional $b$-quarks is reported. The sensitivity is improved by $b$-tagging at least one lower-$p_\text{T}$ jet in addition to the two…
View article: Measurement of the $c$-jet mistagging efficiency in $t\bar{t}$ events using $pp$ collision data at $\sqrt{s}=13$ TeV collected with the ATLAS detector
Measurement of the $c$-jet mistagging efficiency in $t\bar{t}$ events using $pp$ collision data at $\sqrt{s}=13$ TeV collected with the ATLAS detector Open
A technique is presented to measure the efficiency with which $c$-jets are mistagged as b-jets (mistagging efficiency) using $t\bar{t}$ events, where one of the $W$ bosons decays into an electron or muon and a neutrino and the other decays…
View article: Measurement of hadronic event shapes in multijet final states at $\\sqrt{s}=13$ TeV with the ATLAS detector
Measurement of hadronic event shapes in multijet final states at $\\sqrt{s}=13$ TeV with the ATLAS detector Open
A measurement of event-shape variables in proton$-$proton collisions at large momentum transfer is presented using data collected at $\\sqrt{s} = 13$ TeV with the ATLAS detector at the Large Hadron Collider. Six event-shape variables calcu…
View article: Test of the universality of $\tau$ and $\mu$ lepton couplings in $W$-boson decays from $t\bar{t}$ events with the ATLAS detector
Test of the universality of $\tau$ and $\mu$ lepton couplings in $W$-boson decays from $t\bar{t}$ events with the ATLAS detector Open
The Standard Model of particle physics encapsulates our current best understanding of physics at the smallest scales. A fundamental axiom of this theory is the universality of the couplings of the different generations of leptons to the el…
View article: Comparison of fragmentation functions for light-quark- and gluon-dominated jets from $pp$ and Pb+Pb collisions in ATLAS
Comparison of fragmentation functions for light-quark- and gluon-dominated jets from $pp$ and Pb+Pb collisions in ATLAS Open
Charged-particle fragmentation functions for jets azimuthally balanced by a high-transverse-momentum, prompt, isolated photon are measured in 25 pb−1 of pp and 0.49 nb−1 of Pb+Pb collision data at 5.02 TeV per nucleon pair recorded with th…
View article: Combinations of single-top-quark production cross-section measurements and $|f_{\rm LV}V_{tb}|$ determinations at $\sqrt{s}=7$ and 8 TeV with the ATLAS and CMS experimentsCombinations of single-top-quark production cross-section measurements and |f$_{LV}$V$_{tb}$| determinations at $ \sqrt{s} $ = 7 and 8 TeV with the ATLAS and CMS experiments
Combinations of single-top-quark production cross-section measurements and $|f_{\rm LV}V_{tb}|$ determinations at $\sqrt{s}=7$ and 8 TeV with the ATLAS and CMS experimentsCombinations of single-top-quark production cross-section measurements and |f$_{LV}$V$_{tb}$| determinations at $ \sqrt{s} $ = 7 and 8 TeV with the ATLAS and CMS experiments Open
View article: A search for $B-L$ $R$-parity-violating top squarks in $\sqrt{s} = 13$ TeV $pp$ collisions with the ATLAS experiment
A search for $B-L$ $R$-parity-violating top squarks in $\sqrt{s} = 13$ TeV $pp$ collisions with the ATLAS experiment Open
A search is presented for the direct pair production of the stop, the supersymmetric partner of the top quark, that decays through an $R$-parity-violating coupling to a final state with two leptons and two jets, at least one of which is id…
View article: AWAKE readiness for the study of the seeded self-modulation of a 400 GeV proton bunch
AWAKE readiness for the study of the seeded self-modulation of a 400 GeV proton bunch Open
AWAKE is a proton-driven plasma wakefield acceleration experiment. We show that the experimental setup briefly described here is ready for systematic study of the seeded self-modulation of the 400 GeV proton bunch in the 10 m long rubidium…
View article: Measurement of longitudinal flow de-correlations in Pb+Pb collisions at $\sqrt{s_\mathrm{NN}} = 2.76$ and 5.02 TeV with the ATLAS detector : arXiv
Measurement of longitudinal flow de-correlations in Pb+Pb collisions at $\sqrt{s_\mathrm{NN}} = 2.76$ and 5.02 TeV with the ATLAS detector : arXiv Open
View article: Search for the direct production of charginos and neutralinos in $\sqrt{s} = $ 13 TeV $pp$ collisions with the ATLAS detector : arXiv
Search for the direct production of charginos and neutralinos in $\sqrt{s} = $ 13 TeV $pp$ collisions with the ATLAS detector : arXiv Open
View article: Measurement of jet fragmentation in Pb+Pb and $pp$ collisions at $\sqrt{s_\mathrm{NN}} = 2.76$ TeV with the ATLAS detector
Measurement of jet fragmentation in Pb+Pb and $pp$ collisions at $\sqrt{s_\mathrm{NN}} = 2.76$ TeV with the ATLAS detector Open
View article: AWAKE, The Advanced Proton Driven Plasma Wakefield Acceleration Experiment at CERN
AWAKE, The Advanced Proton Driven Plasma Wakefield Acceleration Experiment at CERN Open